Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

382 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor.
Romaniello D, Marrocco I, Belugali Nataraj N, Ferrer I, Drago-Garcia D, Vaknin I, Oren R, Lindzen M, Ghosh S, Kreitman M, Kittel JC, Gaborit N, Bergado Baez G, Sanchez B, Eilam R, Pikarsky E, Paz-Ares L, Yarden Y. Romaniello D, et al. Among authors: oren r. Cancers (Basel). 2020 Aug 24;12(9):2394. doi: 10.3390/cancers12092394. Cancers (Basel). 2020. PMID: 32847130 Free PMC article.
Single-cell epigenetic analysis reveals principles of chromatin states in H3.3-K27M gliomas.
Harpaz N, Mittelman T, Beresh O, Griess O, Furth N, Salame TM, Oren R, Fellus-Alyagor L, Harmelin A, Alexandrescu S, Marques JG, Filbin MG, Ron G, Shema E. Harpaz N, et al. Among authors: oren r. Mol Cell. 2022 Jul 21;82(14):2696-2713.e9. doi: 10.1016/j.molcel.2022.05.023. Epub 2022 Jun 17. Mol Cell. 2022. PMID: 35716669 Free article.
L858R emerges as a potential biomarker predicting response of lung cancer models to anti-EGFR antibodies: Comparison of osimertinib vs. cetuximab.
Marrocco I, Giri S, Simoni-Nieves A, Gupta N, Rudnitsky A, Haga Y, Romaniello D, Sekar A, Zerbib M, Oren R, Lindzen M, Fard D, Tsutsumi Y, Lauriola M, Tamagnone L, Yarden Y. Marrocco I, et al. Among authors: oren r. Cell Rep Med. 2023 Aug 15;4(8):101142. doi: 10.1016/j.xcrm.2023.101142. Epub 2023 Aug 8. Cell Rep Med. 2023. PMID: 37557179 Free PMC article.
Sulfopin is a covalent inhibitor of Pin1 that blocks Myc-driven tumors in vivo.
Dubiella C, Pinch BJ, Koikawa K, Zaidman D, Poon E, Manz TD, Nabet B, He S, Resnick E, Rogel A, Langer EM, Daniel CJ, Seo HS, Chen Y, Adelmant G, Sharifzadeh S, Ficarro SB, Jamin Y, Martins da Costa B, Zimmerman MW, Lian X, Kibe S, Kozono S, Doctor ZM, Browne CM, Yang A, Stoler-Barak L, Shah RB, Vangos NE, Geffken EA, Oren R, Koide E, Sidi S, Shulman Z, Wang C, Marto JA, Dhe-Paganon S, Look T, Zhou XZ, Lu KP, Sears RC, Chesler L, Gray NS, London N. Dubiella C, et al. Among authors: oren r. Nat Chem Biol. 2021 Sep;17(9):954-963. doi: 10.1038/s41589-021-00786-7. Epub 2021 May 10. Nat Chem Biol. 2021. PMID: 33972797 Free PMC article.
Targeting purine synthesis in ASS1-expressing tumors enhances the response to immune checkpoint inhibitors.
Keshet R, Lee JS, Adler L, Iraqi M, Ariav Y, Lim LQJ, Lerner S, Rabinovich S, Oren R, Katzir R, Weiss Tishler H, Stettner N, Goldman O, Landesman H, Galai S, Kuperman Y, Kuznetsov Y, Brandis A, Mehlman T, Malitsky S, Itkin M, Koehler SE, Zhao Y, Talsania K, Shen TW, Peled N, Ulitsky I, Porgador A, Ruppin E, Erez A. Keshet R, et al. Among authors: oren r. Nat Cancer. 2020 Sep;1(9):894-908. doi: 10.1038/s43018-020-0106-7. Epub 2020 Aug 31. Nat Cancer. 2020. PMID: 35121952
382 results